<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; states</title>
	<atom:link href="http://www.tapanray.in/tag/states/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>&#8216;Rigged&#8217; Payment System Limits Biosimilar Access</title>
		<link>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rigged-payment-system-limits-biosimilar-access</link>
		<comments>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/#comments</comments>
		<pubDate>Mon, 02 Apr 2018 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[el dorado]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[large]]></category>
		<category><![CDATA[largest]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[litigations]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigged]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8908</guid>
		<description><![CDATA[As often discussed, market entry of biosimilars, in general, brings a new hope not just for many patients, but also to biosimilar drug manufacturers &#8211; planning to get marketing approvals of these drugs in the United States, the El Dorado &#8230; <a href="http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NHPS: &#8220;One Nation, One Scheme is Enticing&#8221;, But Will It Work?</title>
		<link>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nhps-one-nation-one-scheme-is-enticing-but-will-it-work</link>
		<comments>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/#comments</comments>
		<pubDate>Mon, 12 Mar 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aayog]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Mahatma Jyotiba Phule Jan Aarogya Abhiyan]]></category>
		<category><![CDATA[Modicare]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[National Health Protection Scheme]]></category>
		<category><![CDATA[NHPS]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8903</guid>
		<description><![CDATA[Yet another slogan: “One nation &#8211; One Universal Health Coverage (UHC)” would indeed be enticing for many, including India. Nevertheless, that’s just a hope. Let’s now try to get a message out of what has been recently happening around this &#8230; <a href="http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Improving Drug Quality in India &#8211; A Bizarre Intent</title>
		<link>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-improving-drug-quality-in-india-a-bizarre-intent</link>
		<comments>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/#comments</comments>
		<pubDate>Sun, 28 Jan 2018 23:43:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Inspectors]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Misplaced]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8778</guid>
		<description><![CDATA[On January 16, 2017, quoting a Government source, a media report revealed, “India&#8217;s drug regulator is looking to inspect US pharmaceutical facilities, making critical medicines so that only high-quality products are imported from them.” This intent follows a similar decision &#8230; <a href="http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Happens To Pharma’s Incredible Ride On The ‘Gravy Train’?</title>
		<link>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-happens-to-pharmas-incredible-ride-on-the-gravy-train</link>
		<comments>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/#comments</comments>
		<pubDate>Sun, 25 Sep 2016 23:42:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[gravy]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[incredible]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[Joe]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ride]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[train]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7828</guid>
		<description><![CDATA[India continues to be one of the fastest growing pharmaceutical market of the world with its over 40 percent of the total pharmaceutical produce is exported around the world. Over half of the total exports constitute of formulations, and the &#8230; <a href="http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Healthcare Feature In Raisina Hill’s To-Do List?</title>
		<link>http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-healthcare-feature-in-raisina-hills-to-do-list</link>
		<comments>http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/#comments</comments>
		<pubDate>Mon, 27 Jun 2016 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[Capitol]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CHC]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hill]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[joint]]></category>
		<category><![CDATA[Mantri]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[productive]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[pump-priming]]></category>
		<category><![CDATA[Raisina]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[session]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Yojana’]]></category>
		<category><![CDATA[‘Pradhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7687</guid>
		<description><![CDATA[At the Capitol Hill, while addressing the joint session of the United States Congress, on June 08, 2016, our Prime Minister Mr. Narendra Modi well articulated the following, in his inimitable style: “My to-do list is long and ambitious. It &#8230; <a href="http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier</title>
		<link>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/#comments</comments>
		<pubDate>Mon, 04 Apr 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[lantus XR]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[non-proprietory]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[pen]]></category>
		<category><![CDATA[pre-filled]]></category>
		<category><![CDATA[prescriber]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toujeo]]></category>
		<category><![CDATA[uncharted]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7578</guid>
		<description><![CDATA[A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Great News! But…Would This ‘Golden Goose’ Lay Golden Eggs?</title>
		<link>http://www.tapanray.in/a-great-news-butwould-this-golden-goose-lay-golden-eggs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-great-news-butwould-this-golden-goose-lay-golden-eggs</link>
		<comments>http://www.tapanray.in/a-great-news-butwould-this-golden-goose-lay-golden-eggs/#comments</comments>
		<pubDate>Mon, 15 Dec 2014 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[arthritis]]></category>
		<category><![CDATA[autoimmune]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[bioscience]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[crohn's]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[eggs]]></category>
		<category><![CDATA[engineering]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[exemptia]]></category>
		<category><![CDATA[golden]]></category>
		<category><![CDATA[goose]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[psoriasis]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reverse]]></category>
		<category><![CDATA[rheumatoid]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[USFDAm GVK]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6255</guid>
		<description><![CDATA[On December 9, 2014, international media flashed across the world a great news item from the Indian pharma industry: “The first biosimilar of the world’s top-selling medicine Humira (adalimumab) of AbbVie has been launched in India by Zydus Cadila.” This &#8230; <a href="http://www.tapanray.in/a-great-news-butwould-this-golden-goose-lay-golden-eggs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-great-news-butwould-this-golden-goose-lay-golden-eggs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India…Sell Anywhere in The World”: An Indian Pharma Perspective</title>
		<link>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective</link>
		<comments>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/#comments</comments>
		<pubDate>Mon, 29 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[alert]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Bureau]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global. world]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[letters]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[production]]></category>
		<category><![CDATA[ramparts. red fort]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sell]]></category>
		<category><![CDATA[speech]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[warning]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6039</guid>
		<description><![CDATA[In his Independent Day speech from the ramparts of the Red Fort on August 15, 2014, Indian Prime Minister Modi gave a clarion call to all investors of the world, “Come, make in India”, “Come, manufacture in India”, “Sell in &#8230; <a href="http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug, Patent and Hype: Quo Vadis Pharma Innovation?</title>
		<link>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-patent-and-hype-quo-vadis-pharma-innovation</link>
		<comments>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/#comments</comments>
		<pubDate>Sun, 20 Oct 2013 18:30:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[discover]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[indications]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Nature]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patentable]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Prescire]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Reviews]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2704</guid>
		<description><![CDATA[A recent research report reveals, though the pharmaceutical companies in the United States since mid 2000 have spent over US$ 50 billion every year to discover new drugs, they have very rarely been able to invent something, which can be called significant &#8230; <a href="http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Buying Physicians&#8217; Prescriptions in Cash or Kind: A Global (Dis)Order?</title>
		<link>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder</link>
		<comments>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/#comments</comments>
		<pubDate>Mon, 09 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[congressional]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[educating physicians]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[Family]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globally]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[gut]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hidden]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[induce]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[investigation]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[lesser]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Council. of]]></category>
		<category><![CDATA[medications]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[much travelled]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[phenomenon]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[shun]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[wrenching]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2530</guid>
		<description><![CDATA[Recently a European business lobby reportedly raised its voice alleging pharma Multinational Corporations (MNCs) in China have been &#8216;unfairly targeted&#8217; by a string of investigations into bribery and price-fixing cases despite their generally ‘strong legal compliance’ and has suggested that China &#8230; <a href="http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
